We are now enrolling in a phase 3 study looking at a new treatment for retinal vein occlusion

Retinal vein occlusion(RVO) is a blockage in the retinal veins that drain blood away from the eye. It is a common cause of vision loss affecting 16 million people world wide. It is often caused by atherosclerosis leading to the formation of a blood clot. Treatments are available with steroids, antiVEGF agents and laser. However, frequently patients require extensive, regular treatment to maintain vision. Clearside Biomedical has created an injector that places Triamcinolone Acetonide into the suprachoroidal space of the eye. This is unique in that an old drug is being used more successfully by targeting the affected eye tissue more directly. Indeed in the phase 2 study it was shown that the patients using the suprachoroidal injection combined with standard treatment of antiVEGf had better visual outcomes and required less treatment. Now the phase 3 study is enrolling patients with this condition. It is an exciting study and we are happy to be one of the study sites. If you would like more information, please contact us at 631-924-4300.

Leave a Reply

Your email address will not be published. Required fields are marked *